New Treatment for Liver Fibrosis Discovered

Among patients with nonalcoholic steatohepatitis (NASH)-related fibrosis a new drug treatment has been discovered.

In patients with nonalcoholic steatohepatitis (NASH)-related fibrosis, the newly identified drug mirrors a hormone in the body improved liver fibrosis and liver inflammation condition, stated study published in The New England Journal of Medicine (). //

“Identifying an effective drug for NASH is extremely promising for patients as currently there are no FDA-approved therapies for this condition,” said Rohit Loomba, MD, the study’s first author and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. “NASH can adversely impact the quality of life in patients and can progress to cirrhosis. Its complications can lead to death or liver transplantation.”

Fatty Liver Disease: A Growing Health Problem in India - Causes, Symptoms, Diagnosis, Treatment
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India.

‘In patients with nonalcoholic steatohepatitis (NASH)-related fibrosis a new drug target discovered reduced liver fibrosis by 27%. #liverdisease #livertreatment #alcoholicliver’

“Our findings will further the science of this disease and provide a potential new treatment option to those affected by NASH-related fibrosis.”

NASH-related Fibrosis Treatment

The researchers found that the drug, called Pegozafermin, mimicked fibroblast growth factor 21 (FGF21) — a liver-secreted peptide hormone that is naturally produced in the body.

FGF21 controls energy use in the body and lipid metabolism in the liver. It has also been shown in previous studies to lower blood glucose and insulin levels, reducing body weight and liver fat.

“The study’s results show that the new potential treatment not only improves fibrosis but also improves inflammation and liver injury along with significant improvements across multiple non-invasive biomarkers of NASH activity and scarring,” said Loomba, gastroenterologist and hepatologist at UC San Diego Health.

Fibroscan for Fatty Liver Cirrhosis and Fibrosis - Causes, Symptoms, Treatment
Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to estimate the degree of fatty infiltration in the liver.

The 24-week, randomized clinical trial involved 222 participants with NASH assigned to either receive the drug or a placebo.

Of the patients who received the drug at a higher dose, approximately 27% showed an improvement in liver fibrosis, relative to 7% of the patients who received the placebo. The most frequent reported side effect from the drug were gastrointestinal in nature, including nausea.

Test Your Knowledge on Liver Transplantation

Introduction

Liver transplantation is a surgical procedure that involves the removal of a diseased liver and replacing it or transplanting it with a whole or a portion of a healthy liver from a human donor.

People may be considered for liver transplantation when their liver fails to function properly due to infection, alcohol or cancer ().

Top 10 Ways to Cleanse the Liver
The liver acts as a fine filter in removing toxins out of the bloodstream. Some foods can improve the process the liver detoxification and improve its function.

In this quiz you will find answers for the following questions:

Indications for liver transplantation ()
Long term results of liver transplantation ()
Types of liver transplantation ()
Complications of liver transplantation ()
Signs of rejection after liver transplantation ()
Diagnosis of rejection after liver transplantation ()
About anti-rejection drugs ()

Currently, there are no medications approved by the U.S. Food and Drug Administration available for the treatment of NASH, which is a type of nonalcoholic fatty liver disease (NAFLD).

According to the National Institutes of Health, approximately 24% of U.S. adults have NAFLD, and about 6% have NASH.

NAFLD and NASH are considered silent diseases with little to no symptoms; however, individuals who are overweight, have type 2 diabetes or have a family member with NAFLD are at a higher risk of developing the disease. NAFLD — which is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol — can lead to cirrhosis, liver cancer and liver failure.

Loomba adds next steps for this research will be a larger, multi-center, international trial with a more diverse patient population and longer treatment period to better assess the safety of the drug.

“If successfully shown to be both safe and effective in a larger Phase 3 trial, this drug could be used to treat millions of patients with NASH, including our patients at UC San Diego Health,” said Loomba.

Reference:

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH - (https://www.nejm.org/doi/10.1056/NEJMoa2304286)

Source-Eurekalert